Eisai Co Ltd (4523.T) News| Reuters.com
Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

5,663JPY
2:00am EDT
Change (% chg)

¥254 (+4.70%)
Prev Close
¥5,409
Open
¥5,549
Day's High
¥5,704
Day's Low
¥5,538
Volume
1,174,300
Avg. Vol
993,436
52-wk High
¥8,996
52-wk Low
¥5,538

Select another date:

Fri, May 13 2016

BRIEF-U.S. FDA expands approval of Eisai's cancer drug Lenvima

* FDA Approves Eisai's Lenvima (Lenvatinib) For The Treatment Of Patients With Advanced Renal Cell Carcinoma In Combination With Everolimus Following Prior Anti-Angiogenic therapy Source text for Eikon: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Eisai signed cooperation agreements with Pharmstandard

* Co, Pharmstandard signed cooperation agreements relating to localised production of Eisai products in Russia Source text for Eikon: Further company coverage: (Reporting by Vishal Sridhar)

FDA approves Eisai's drug Halaven for type of soft tissue cancer

The U.S. Food and Drug Administration approved Eisai Co Ltd's drug derived from sea sponge for a rare type of soft tissue cancer.

CORRECTED-FDA approves Eisai's drug Halaven for type of soft tissue cancer (Jan. 28)

Jan 28 The U.S. Food and Drug Administration approved Eisai Co Ltd's drug derived from sea sponge for a rare type of soft tissue cancer.

Select another date: